Adjuvant chemotherapy for esophageal cancer guided by blood test
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove all visible esophageal cancer, with clear margins, within the last 4 to 16 weeks.
- You have a blood test result showing minimal residual disease (MRD-positive) after surgery.
- Your cancer type is squamous cell carcinoma of the esophagus (with some exceptions).
- You are age 19 or older and in good general health (able to perform daily activities).
- Your tumor tissue from a biopsy or surgery and blood samples are available for testing.
- If you are premenopausal and able to have children, a pregnancy test and contraception are required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy or radiation for older adults with advanced or recurrent esophageal cancer. The goal is to see if this combination is safe and effective in treating the cancer and possibly slowing its growth.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests whether combining the immunotherapy drug tislelizumab with chemotherapy before and after surgery helps treat esophageal squamous cell cancer better than just surgery alone. It aims to shrink the tumor before surgery and reduce the chance of the cancer coming back afterward.
This trial tests whether giving an immunotherapy drug called tislelizumab before surgery helps shrink esophageal cancer and improve outcomes. It is for people newly diagnosed with early-stage squamous cell esophageal cancer that can be removed surgically.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.